News & Updates

Treatment with low-dose aspirin, when added to calcium, early in pregnancy does not appear to provide any benefit in terms of reducing the incidence of pre-eclampsia as well as caesarean section or other important neonatal outcomes in high-risk women, according to a study.

Cannabis users are at increased risk of major adverse cardiovascular events (MACE), according to the results of a meta-analysis based on real-world data.

Patients with idiopathic hyperaldosteronism (IHA) treated with esaxerenone show improved vascular function and reduced peripheral arterial stiffness, reports a study.

New drug applications approved by US FDA as of 16-31 May 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Patients with atrial fibrillation (AF) who have been treated with the long-acting factor XI inhibitor abelacimab may undergo invasive procedures, as shown by the low rates of bleeding in a recent study.

During outpatient heart failure (HF) care, patients with lower scores in the Kansas City Cardiomyopathy Questionnaire-12 (KCCQ-12) are at greater risk of hospitalizations and mortality, suggests a study. Moreover, those with scores <25 appear to have the highest risk.

One-month treatment with dual antiplatelet therapy (DAPT) results in similar adverse events and a reduction in total bleeding risk when compared with prolonged DAPT, a study has shown.

Treatment with inclisiran monotherapy demonstrates good tolerability and better reduction in low-density lipoprotein cholesterol (LDL-C) levels when compared with ezetimibe and placebo in patients without atherosclerotic cardiovascular disease (ASCVD), reports a study.